General Archives - Spark Newswire

4 minute read

Disc Presents Initial Data From Phase 2 BEACON Trial Of Bitopertin In Patients With Erythropoietic Protoporphyria At European Hematology Association 2023 Congress

Today, 10:09 AM

Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertin Patients reported significant improvements in sunlight

IRON

1 minute read

AngioDynamics Divests Dialysis Portfolio And Biopsy Product Line To Merit Medical Systems For $100M

By Nabaparna Bhattacharya

Today, 10:02 AM

AngioDynamics, Inc. (NASDAQ: ANGO)

ANGO

4 minute read

Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia’s AI Technology Stirs Concern: Today’s Top Stories

By Vandana Singh

Today, 9:56 AM

Financial Times

AZN

1 minute read

Walgreens Boots Sells Remaining Stake In Option Care Health For $330M

By Nabaparna Bhattacharya

Today, 9:42 AM

Walgreens Boots Alliance, Inc. (NASDAQ: WBA)

ABC

1 minute read

AstraZeneca’s Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder

By Vandana Singh

Today, 8:44 AM

AstraZeneca Plc (NASDAQ: AZN)

AZN

2 minute read

Disney Fires Up Sports Streaming War Against India’s Richest Man On His Home Turf

By Shomik Sen Bhattacharjee

Today, 8:25 AM

This article was first published on the Benzinga India Portal.

DIS

1 minute read

AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes

By Vandana Singh

Today, 8:14 AM

AstraZeneca plc (NASDAQ: AZN) has entered into a

AZN

1 minute read

Unanimous Support for AstraZeneca and Sanofi’s Nirsevimab: Next Generation RSV Treatment on the Horizon

By Vandana Singh

Today, 8:07 AM

The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t

AZN